| Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company's poster presentations examined the age of onset of SAD in participants in. |
businesswire.com |
2025-04-17 12:30:00 |
Czytaj oryginał (ang.) |
| Vistagen to Present at the 2025 Anxiety and Depression Association Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company's poster presentations will explore the age of onset of social anxiety diso. |
businesswire.com |
2025-03-19 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen to Participate in Stifel 2025 Virtual CNS Forum |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel's 2025 Virtual CNS Forum. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m. |
businesswire.com |
2025-03-04 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication |
Vistagen Therapeutics, Inc.'s results from the PALISADE-3 and PALISADE-4 studies, using fasedienol for the treatment of patients with Social Anxiety Disorder, expected in 2025. Fifth proof-of-concept of pherine drug use was achieved targeting patients with cancer cachexia; Further IND enabling efforts underway to begin phase 2 studies for this program in the United States. The global cancer cachexia market size is projected to reach $3.76 billion by 2032. |
seekingalpha.com |
2025-02-14 20:19:47 |
Czytaj oryginał (ang.) |
| Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript |
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ET Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - Chief Executive Officer and Director Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants John Boyle - William Blair Operator Good day. Thank you for standing by. |
seekingalpha.com |
2025-02-13 22:47:38 |
Czytaj oryginał (ang.) |
| VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates |
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago. |
zacks.com |
2025-02-13 20:56:07 |
Czytaj oryginał (ang.) |
| Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 2024, and provided a corporate update. “We had a very productive quarter, with both PALISADE-3 and PALISADE-4 advancing towards expected top-line. |
businesswire.com |
2025-02-13 18:30:00 |
Czytaj oryginał (ang.) |
| Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a. |
businesswire.com |
2025-02-06 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of neuropathic pain. The patent will not expire until at least 2034 and is part of Vistage. |
businesswire.com |
2025-02-05 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, place. |
businesswire.com |
2025-01-10 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen to Present at the Stifel 2024 Healthcare Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35. |
businesswire.com |
2024-11-14 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript |
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Julian Pino - Stifel Andrew Tsai - Jefferies Myles Minter - William Blair Madison El-Saadi - B. Riley Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call. |
seekingalpha.com |
2024-11-10 09:43:56 |
Czytaj oryginał (ang.) |
| VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates |
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago. |
zacks.com |
2024-11-07 22:31:31 |
Czytaj oryginał (ang.) |
| Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. “We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute t. |
businesswire.com |
2024-11-07 18:20:00 |
Czytaj oryginał (ang.) |
| Vistagen to Present at the 2024 Neuroscience Education Institute Congress |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic. |
businesswire.com |
2024-11-05 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update. |
businesswire.com |
2024-11-01 10:30:00 |
Czytaj oryginał (ang.) |
| Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder |
Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one of the two studies, PALISADE-3 and PALISADE-4, to succeed in supporting a filing for marketing approval. VTGN had $108.4M as of June 30, 2024, but increased R&D expenses may accelerate cash burn, and the Company could look to use its at-the-market facility or conduct an offering. |
seekingalpha.com |
2024-10-15 11:25:52 |
Czytaj oryginał (ang.) |
| VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know |
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-11 17:01:12 |
Czytaj oryginał (ang.) |
| Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day |
SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join together in New York City on Oc. |
businesswire.com |
2024-10-09 12:30:00 |
Czytaj oryginał (ang.) |
| Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray in U.S. registration-directed Phase 3 development for. |
businesswire.com |
2024-09-23 12:30:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy |
VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-09-06 17:00:34 |
Czytaj oryginał (ang.) |
| Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript |
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Madison Elsaadi - B. Riley Securities Operator Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call. |
seekingalpha.com |
2024-08-13 23:05:28 |
Czytaj oryginał (ang.) |
| VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates |
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago. |
zacks.com |
2024-08-13 22:30:32 |
Czytaj oryginał (ang.) |
| 3 Stocks Under $15 That Could Make You a Millionaire |
Lately, the stock market has been soaring thanks mostly to growth stocks trading at sky-high valuations. While rate cuts could potentially boost markets, caution is still warranted for most investors. |
investorplace.com |
2024-07-26 10:20:00 |
Czytaj oryginał (ang.) |
| Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript |
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2024 Earnings Conference Call June 11, 2024 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Operator Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-06-11 22:41:02 |
Czytaj oryginał (ang.) |
| Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update. “Vistagen's fiscal 2024 proved to be a year full of remarkable accomplishments. Most notably, with. |
businesswire.com |
2024-06-11 20:20:00 |
Czytaj oryginał (ang.) |
| Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fis. |
businesswire.com |
2024-06-07 12:30:00 |
Czytaj oryginał (ang.) |
| Vistagen to Present at the Jefferies Global Healthcare Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference taking place June 5 and 6, 2024 in New York City. Jefferies Global Healthcare Conference Shawn Singh, Chief Executive Of. |
businesswire.com |
2024-05-29 12:30:00 |
Czytaj oryginał (ang.) |
| Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2. |
businesswire.com |
2024-05-23 12:30:00 |
Czytaj oryginał (ang.) |
| 3 Must-Have Penny Stocks to Boost Your 2024 Portfolio |
Penny stocks can be super volatile, but the potential of a modest investment ballooning into a multi-bagger is tough to pass up. These stocks represent the riskier end of the public equity range. |
investorplace.com |
2024-05-14 10:59:00 |
Czytaj oryginał (ang.) |